Navigation Links
Bionovo to Present Recent Findings of BZL101, Its Anti-cancer,Agent, at the American Association of Cancer Research

EMERYVILLE, Calif., April 16, 2007 /PRNewswire-FirstCall/ -- Bionovo, Inc. will present findings on the mechanism of action of its anti-cancer agent BZL101, which is advancing to Phase 1/2 clinical testing for late stage breast cancer at the American Association of Cancer Research (AACR) being held at the Los Angeles Convention Center in Los Angeles, CA, April 14 - 17, 2007.

Bionovo's poster presentation will describe the pathway for cancer cell apoptosis (cell death) induced by BZL101 while leaving normal cells unaffected. As explained by Dr. Emma Shtivelman, Director of Cancer Research at Bionovo, the ability of BZL101 to induce apoptosis is due to attenuation of mitochondrial transmembrane potential (MTP) leading to the release of reactive oxygen species, causing inhibition of glycolysis and ending with induction of oxidative DNA damage.

A paper on BZL101's mechanism of action and unique selective properties based on the company's initial Phase 1 clinical trial was published late last year in the peer-reviewed journal, Breast Cancer Research and Treatment.

"BZL101's mechanism of action and unique selective properties" said Dr. Isaac Cohen, President and CEO of Bionovo, "are a result of some of the biological differences between cancer cells and normal cells. We are hoping that capitalizing on the difference will result in a safe and effective treatment for cancer."

Bionovo, Inc.

Bionovo is a drug development company focusing on the discovery of novel pharmaceutical agents for cancer and women's health. The company has two drugs in clinical testing. MF101 is in Phase 2 for quality of life conditions associated with menopause, and BZL101 is in Phase 1/2 for the treatment of advanced breast cancer. The company has an additional pipeline of drugs in development for breast cancer, pancreatic cancer and other menopausal symptoms with a total of 4 drug candidates expected to be in
'"/>




Page: 1 2 3

Related medicine technology :

1. Bionovos MF101 Shows Positive Safety, Tolerability and Efficacy in Phase 2 Trial
2. The Past, Present and Future of HLA Typing
3. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
4. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
6. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
7. Generex Biotechnology to Make Presentations At 46th Annual Meeting of the European Society of Pediatric Endocrinology
8. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
9. ViaCell to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
10. Accelrys to Present to Investors at C.E. Unterberg Emerging Growth Opportunities Conference
11. Metabasis to Present at C.E. Unterberg, Towbin Emerging Growth Conference and Attend Pacific Growth Equities Conference
Post Your Comments:
(Date:11/25/2008)...spondents against expanding statin use broadly in ...S, N.J., Nov. 25 JUPITER, a clinic...diovascular risk of healthy patients with elevated...der adults, according to a national poll directed ...ook part in the online poll conducted by medical n...
(Date:11/25/2008).... 25 Pharmacyclics, Inc....ny has completed a Phase 1,clinical trial with PC...l-molecule Factor VIIa inhibitor. The trial was co...luate the safety and pharmacologic effect of,PCI-...ed in a linear dose,response in the International...
(Date:11/24/2008)...SAKA, Japan, Nov. 24 Takeda Pharma...idiary, Takeda Global Research & Development C...tis Advisory Committee of the U.S. Food and Drug A...ve febuxostat for the treatment of hyperuricemia ...favor of approval, with one panel member abstainin...
(Date:11/24/2008)... Cancer Awareness Month , , Oak Brook, Ill.... Society for Gastrointestinal Endoscopy (ASGE) and...up this November to raise awareness about pancreat...d the resources that are available for them. , ...e of cancer deaths in the U.S. In 2008, an estimat...
Breaking Medicine Technology:Dramatic JUPITER Findings Fail to Sway Prescribing Behavior, Poll Shows 2Dramatic JUPITER Findings Fail to Sway Prescribing Behavior, Poll Shows 3Pharmacyclics Announces Completion of Phase 1 Clinical Trial of Factor VIIa Inhibitor PCI-27483 2Pharmacyclics Announces Completion of Phase 1 Clinical Trial of Factor VIIa Inhibitor PCI-27483 3Pharmacyclics Announces Completion of Phase 1 Clinical Trial of Factor VIIa Inhibitor PCI-27483 4Arthritis Advisory Committee Recommends FDA Approval of Febuxostat for the Treatment of Hyperuricemia in Patients With Gout 2Arthritis Advisory Committee Recommends FDA Approval of Febuxostat for the Treatment of Hyperuricemia in Patients With Gout 3ASGE and The Pancreatic Cancer Action Network Partner to Raise Awareness About Pancreatic Cancer 2ASGE and The Pancreatic Cancer Action Network Partner to Raise Awareness About Pancreatic Cancer 3ASGE and The Pancreatic Cancer Action Network Partner to Raise Awareness About Pancreatic Cancer 4ASGE and The Pancreatic Cancer Action Network Partner to Raise Awareness About Pancreatic Cancer 5ASGE and The Pancreatic Cancer Action Network Partner to Raise Awareness About Pancreatic Cancer 6New Survey Finds Overwhelming Majority of Working Americans Not Financially Prepared for Disability Would Rely on Sources Other than Themselves for S 19037 1New Survey Finds Overwhelming Majority of Working Americans Not Financially Prepared for Disability Would Rely on Sources Other than Themselves for S 19037 2New Survey Finds Overwhelming Majority of Working Americans Not Financially Prepared for Disability Would Rely on Sources Other than Themselves for S 19037 3New Survey Finds Overwhelming Majority of Working Americans Not Financially Prepared for Disability Would Rely on Sources Other than Themselves for S 19037 4History Making Obesity Awareness Event Scheduled to Take Place in Washington DC on June 17 2008 19035 1History Making Obesity Awareness Event Scheduled to Take Place in Washington DC on June 17 2008 19035 2Shire Launches Nationwide Adult ADHD Mobile Awareness Tour 5312 1Shire Launches Nationwide Adult ADHD Mobile Awareness Tour 5312 2Shire Launches Nationwide Adult ADHD Mobile Awareness Tour 5312 3Shire Launches Nationwide Adult ADHD Mobile Awareness Tour 5312 4Shire Launches Nationwide Adult ADHD Mobile Awareness Tour 5312 5Ancient protein offers clues to killer condition 3266 1Ancient protein offers clues to killer condition 3266 2
...720 Mechanisms in Multiple,Sclerosis May Include D... studies suggest FTY720 stimulates cells,that may ...f the,CNS affected by multiple sclerosis , ·...,sclerosis Phase II clinical study found that the ...s significantly lower in the,FTY720 groups compare...
...)--May 4, 2007 - New data from a,randomized, doubl...E(R) (glatiramer acetate injection) along with the... (Gd)-enhancing lesions,of the brain by 63 percent...ing multiple sclerosis (RRMS), as measured by,magn...ceiving,COPAXONE(R) alone. Additionally, the nine-...
Other Medicine Technology:Data to be presented at AAN Meeting -Study results of drug,candidate for MS 2Data to be presented at AAN Meeting -Study results of drug,candidate for MS 3Data to be presented at AAN Meeting -Study results of drug,candidate for MS 4Data to be presented at AAN Meeting -Study results of drug,candidate for MS 5Data to be presented at AAN Meeting -Study results of drug,candidate for MS 6Data to be presented at AAN Meeting -Study results of drug,candidate for MS 7Data to be presented at AAN Meeting -Study results of drug,candidate for MS 8Data to be presented at AAN Meeting -Study results of drug,candidate for MS 9Treatment with Copaxone Plus Minocycline Showed Substantial,Reduction of Disease Activity in Patients with Active,Relapsing-Remitting Multiple Sclerosis 2Treatment with Copaxone Plus Minocycline Showed Substantial,Reduction of Disease Activity in Patients with Active,Relapsing-Remitting Multiple Sclerosis 3Treatment with Copaxone Plus Minocycline Showed Substantial,Reduction of Disease Activity in Patients with Active,Relapsing-Remitting Multiple Sclerosis 4Treatment with Copaxone Plus Minocycline Showed Substantial,Reduction of Disease Activity in Patients with Active,Relapsing-Remitting Multiple Sclerosis 5
(Date:12/2/2008)...lifornia Health System Builds Resilient, Cost and ..., HOPKINTON, Mass., Dec. 2 EMC ...formation infrastructure solutions, today announce...S), a regional system of six hospitals spanning th...ervers and implemented business continuity functio...
(Date:12/2/2008)...NVER, Dec. 2 Barotz Dental is now ...ng LANAP(TM) (Laser Assisted New Attachment,Proce...col that is patented,and FDA approved for new att... LANAP removes diseased tissue, without removin...sue around teeth, minimizes pain and discomfort to...
(Date:12/2/2008)...SHERS, Ind., Dec. 2 A number of re...e in childhood obesity, the health risks in,overw...alue of cereals and,other foods kids consume. Ye...offers all natural, freeze-dried real fruit produc... but also provide most, if not all, of the daily f...
(Date:12/2/2008)... Zicam Cold & Flu Compa...ers stay one step ahead of cold and flu. , ...er 2, 2008 -- Matrixx Initiatives, Inc., makers of...h of the Zicam® Cold & Flu Companion mobil...d,s first Android-powered phone. The same mobile a...
Breaking Medicine News(10 mins):Health News:Daughters of Charity Health System Improves IT Efficiency and Accelerates Time-to-Treatment with EMC 2Health News:Daughters of Charity Health System Improves IT Efficiency and Accelerates Time-to-Treatment with EMC 3Health News:Daughters of Charity Health System Improves IT Efficiency and Accelerates Time-to-Treatment with EMC 4Health News:Barotz Dental Now Offering Laser Gum Therapy 2Health News:Moms Find Fun, Healthy Snacks That Help Fight Childhood Obesity 2Health News:Moms Find Fun, Healthy Snacks That Help Fight Childhood Obesity 3Health News:Zicam Launches "Cold & Flu Companion" Mobile Application 2Health News:Zicam Launches "Cold & Flu Companion" Mobile Application 3
...ing weight by dietary changes and increased physic...condition where blood glucose// levels are higher ...ese are the results of a new study that was publis...Care, of women who participated in the Diabetes Pr...
...e being hit the most by obesity-related disorders....ne by doctors that fails to// detect these problem...ight divided by height- is used in the standard me...ing to the experts, East and South Asians were aff...
...n Canada ahead of HIV/AIDS, diabetes and car accid...inal communities. With World// Suicide Prevention ... from the Canadian Institutes of Health Research (...lenges posed by suicide, its causes and possible p...
...er a period of 30 years and has infected many peop...Recently, 3 people in Delhi// have tested positive...rs who transmit chikungunya fever to human. The N...able Diseases (NICD) tested 6 blood samples of whi...
Other Medicine News:Health News:Bladder Control following Weight loss in women with Prediabetes 2Health News:Bladder Control following Weight loss in women with Prediabetes 3Health News:Getting Serious About Suicide Prevention 2
VACUETTE paediatric tubes have decreased sample volumes and are ideal for small childrens' veins and geriatric patients.
BD Vacutainer® Plus Plastic Serum Tubes have spray-coated silica and are used for serum determinations in chemistry, serology, and immunohematology.
Inquire
The inner wall of the tube is coated with spray-dried lithium, ammonium or sodium heparin. These additives are anti-coagulants, which activate anti-thrombins, thus blocking the coagulation cascade of
Medicine Products: